Relevant bibliographies by topics / Non-permissive mismatche

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic 'Non-permissive mismatche'

Author: Grafiati
Published: 9 March 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Non-permissive mismatche.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Non-permissive mismatche"

1

Chiusolo, Patrizia, Teresa Lamparelli, Giuseppe Sapienza, et al. "The Impact of Aminoacid Substitution at Position 116 Class I HLA, in Unrelated Donor Transplants." Blood 134, Supplement_1 (2019): 4620. http://dx.doi.org/10.1182/blood-2019-130614.

Full text
Abstract:
Background : The role of aminoacid substitution at position 116 of class I HLA antigens, has been the subject of several contributions, suggesting the possibility of permissive or non permissive mismatches. Hypothesis. Permissive mismatched at position AA116, yield outcomes comparable to 10/10 matched grafts and superior to AA116 non permissive mismatches. Patients: We have analyzed 358 unrelated donor transplants (UD) to test this hypothesis. All donors were matched at class II for DRB1 and DQ alleles; 226 were also matched at high resolution for A,B and C alleles; 84 had 1 permissive AA116 m
APA, Harvard, Vancouver, ISO, and other styles
2

Shaw, Bronwen E., Katharina Fleischhauer, Mari Malkki, et al. "Permissive HLA-DPB1 Mismatching Compared to a Non-Permissive Mismatching Significantly Improves Overall Survival Following Allogeneic Transplantation In Patients with Both 10/10 and 9/10 Matched Unrelated Donors." Blood 116, no. 21 (2010): 227. http://dx.doi.org/10.1182/blood.v116.21.227.227.

Full text
Abstract:
Abstract Abstract 227 It is well established that the use of a donor matched for 9–10/10 alleles at HLA-A,-B,-C,-DRB1,-DQB1 significantly improves overall survival (OS) after unrelated donor (UD) haematopoietic stem cell transplantation (HSCT). Whilst the matching status for HLA-DPB1 alleles has been shown to influence transplant complications (relapse and graft-versus-host disease (GVHD), its impact on survival has not been well defined. The current unmet need in clinical practice is an approach to stratify selection criteria when a clinician is confronted with the choice between several 10/1
APA, Harvard, Vancouver, ISO, and other styles
3

Michallet, Mauricette, Mohamad Sobh, Hélène Labussière-wallet, et al. "Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Peripheral Blood or Bone Marrow Donors: The Impact of HLA Matching Including HLA-DPB1 Allele in a Multivariable Risk Model." Blood 126, no. 23 (2015): 3213. http://dx.doi.org/10.1182/blood.v126.23.3213.3213.

Full text
Abstract:
Abstract Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from unrelated donors has been increasingly used worldwide in the last decade in patients with hematological malignancies when HLA-identical sibling donors are unavailable. Identification of the HLA locus matching at the allele level is important in optimizing transplantation outcomes by minimizing non-relapse mortality (NRM) as well as in enhancing the graft-versus-leukemia effect. It has been demonstrated that patients with HSC donors matched on HLA-A, -B, -C, -DRB1, and -DQB1 alleles can have different outc
APA, Harvard, Vancouver, ISO, and other styles
4

Arrieta-Bolanos, Esteban, Pietro Crivello, Meilun He, et al. "A Refined Model of HLA-DP Permissiveness Improves Stratification of Acute Graft-Versus-Host Disease Risks after Unrelated Hematopoietic Cell Transplantation: A Retrospective Study from the CIBMTR." Blood 138, Supplement 1 (2021): 2890. http://dx.doi.org/10.1182/blood-2021-146957.

Full text
Abstract:
Abstract Introduction: Permissive HLA-DPB1 mismatches defined by the T-cell epitope (TCE) model are an established selection criterion for unrelated donors in allogeneic hematopoietic cell transplantation (alloHCT) (Dehn et al. Blood 2019). Based on biological evidence, the TCE model has classified HLA-DPB1 alleles into at least three functional groups, one of which (TCE group 3; TCE3) houses a large number of alleles with different structural and functional characteristics. We have recently shown that structurally close HLA-DP allotypes have similar peptide-binding motifs and share a signific
APA, Harvard, Vancouver, ISO, and other styles
5

Shike, Hiroko, and Aiwen Zhang. "HLA and Non-HLA Factors for Donor Selection in Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide GvHD Prophylaxis." Cells 13, no. 24 (2024): 2067. https://doi.org/10.3390/cells13242067.

Full text
Abstract:
Human leukocyte antigen (HLA) mismatches in stem cell transplantation can be well-tolerated with the use of post-transplant cyclophosphamide (PTCy) for graft-versus-host-disease (GvHD) prophylaxis. Haploidentical (Haplo) and HLA-mismatched unrelated donors become acceptable donors. This review focuses on Haplo and unrelated donor selection in the context of PTCy-transplant for hematological malignancy, in comparison with conventional GvHD prophylaxis. Evaluating patient’s donor-specific antibody (DSA) is critical in donor selection regardless of donor type or the use of PTCy. High DSA levels a
APA, Harvard, Vancouver, ISO, and other styles
6

Oran, Betul, Rima M. Saliba, Yudith Carmazzi, et al. "Increased Disease Progression in HLA-a, -B, -C, -DRB1 and -DBP1 Matched Recipients of Unrelated Donor Transplants with Peripheral Blood Is Independent of Risk Groups By Disease Risk Index." Blood 126, no. 23 (2015): 2005. http://dx.doi.org/10.1182/blood.v126.23.2005.2005.

Full text
Abstract:
Abstract The use of unrelated donors matched in all alleles of HLA-A, -B, -C, and -DRB1 loci has been associated with superior outcomes compared with those having 1 or more mismatches. Recent studies showed increased transplant-related mortality (TRM) with the use of HLA-DPB1 mismatched donors supporting the notion that the ideal volunteer unrelated donor should fully match at HLA-A, -B, -C, and -DRB1 and lack -DPB1 mismatches. The issue of the effect of HLA-DPB1 mismatch on the disease progression rate is still controversial and we aimed to investigate the impact of HLA-DPB1 mismatch in the g
APA, Harvard, Vancouver, ISO, and other styles
7

Metzing, Maximilian, Pietro Crivello, Thuja Meurer, et al. "HLA-DM Mediates Permissiveness of HLA-DPB1 T Cell Epitope Mismatches in Unrelated HCT." Blood 134, Supplement_1 (2019): 3211. http://dx.doi.org/10.1182/blood-2019-129921.

Full text
Abstract:
Introduction: In 8/8 matched unrelated donor (UD) hematopoietic cell transplantation (HCT), permissive HLA-DPB1 (DP) mismatches within the same functional T Cell Epitope (TCE) group are associated with better outcomes compared to non-permissive mismatches across different TCE groups (Fleischhauer, Blood 2017). This clinical advantage has been shown to be associated with limited in vitro T cell alloreactivity (Meurer, Front Immunol 2019), which in turn is dependent on polymorphic peptide contact amino acids in the DP molecule (Crivello, Biol Blood Marrow Transplant 2015). The HLA class II immun
APA, Harvard, Vancouver, ISO, and other styles
8

Ruggeri, Annalisa, Carlheinz Mueller, Liesbeth C. de Wreede, et al. "Association of Donor-Recipient HLA Matching with Outcome of Unrelated Donor Hematopoietic Stem Cell Transplantation: A Study from the Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT)." Blood 134, Supplement_1 (2019): 3281. http://dx.doi.org/10.1182/blood-2019-125369.

Full text
Abstract:
Introduction: Optimal HLA matching is associated with clinical outcome of unrelated donor (UD) hematopoietic cell transplantation (HCT)(Pidala, Blood2014, Morishima, Blood2015, Fürst, Blood2013), but a comprehensive analysis addressing this question in European transplant centers has not yet been performed. Within the CTIWP of EBMT, we have addressed this issue in adultsreceiving an UD-HCT from 2000 to 2015. Methods: All consecutive cases of UC-HCT with available 6-loci high resolution (2nd field) HLA-A, -B, -C, -DRB1, -DQB1, -DPB1 typing for both patient and donor and ARD-level matching for a
APA, Harvard, Vancouver, ISO, and other styles
9

Smallbone, Portia, Kai Cao, Rima M. Saliba, et al. "HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide." Blood 144, Supplement 1 (2024): 4937. https://doi.org/10.1182/blood-2024-200238.

Full text
Abstract:
Background Disease progression, graft-versus-host disease (GvHD) and non-relapse mortality are the main causes of failure after allogeneic hematopoietic cell transplantation (HCT). There have been many studies focusing on the biological models of HLA-DPB1 mismatching, namely permissiveness according to T-cell epitope (TCE) groups to determine their association with the risks of non-relapse mortality (NRM) and GvHD/relapse. Most studies were conducted prior to the advent of post-transplant cyclophosphamide (PTCy) as standard GvHD prophylaxis for matched unrelated donor (MUD) transplants. Thus,
APA, Harvard, Vancouver, ISO, and other styles
10

Lee, Yoo Jin, Joon Ho Moon, In Hee Lee, et al. "Killer Cell Immunoglobulin-like Receptor Ligand Matching Determines the Post-Transplant High Risk Groups Among Patients with Permissive HLA Mismatch in Unrelated Donor Hematopoietic Cell Transplantation." Blood 128, no. 22 (2016): 4566. http://dx.doi.org/10.1182/blood.v128.22.4566.4566.

Full text
Abstract:
Abstract Background: Human leukocyte antigen (HLA) matching between donor and recipient is a key part of successful allogeneic hematopoietic cell transplantation (allo-HCT). The HCT from the unrelated donor (UD) with one allele/antigen mismatch (MM) can be as beneficial as HCT from perfectly matched donor. For the remaining patients, the donors with permissive mismatches may be the option. In HLA-mismatched transplantation, the patient and donor can also be mismatched for their killer cell immunoglobulin-like receptor (KIR) ligands that recognize allotypic determinants shared by certain HLA cl
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Non-permissive mismatche"

1

CRIVELLO, PIETRO. "New molecular insights into HLA immunogenicity." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2012. http://hdl.handle.net/10281/29854.

Full text
Abstract:
Alloreactivity is the major barrier to solid organ and hematopoietic stem cell transplantation (HSCT), determining important clinical events such as graft rejection and graft versus host disease. This biological phenomenon is due to the immunogenicity of allogeneic Human Leukocyte Antigens (HLA) expressed in transplanted tissues and recognized by T cell receptor (TCR) on the surface of alloreactive T cells. In the past, the hosting laboratory identified an immunogenic T cell epitope (TCE) encoded by a subset of HLA-DPB1 alleles, thereby defining permissive and non-permissive DPB1 mismatches be
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Non-permissive mismatche' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography